title: Midterm results of low-dose intravitreal triamcinolone as adjunctive treatment for proliferative vitreoretinopathy.
abstract: OBJECTIVE
  To evaluate the midterm anatomical and functional outcomes of intravitreal injection of low-dose triamcinolone acetonide in silicone oil-filled eyes as an adjunctive treatment for proliferative vitreoretinopathy.
  
  
  METHODS
  This is a retrospective interventional case series. Patients with proliferative vitreoretinopathy grade C or D received pars plana vitrectomy combined with silicone oil tamponade and intravitreal injection of 2 mg of triamcinolone acetonide in the first stage and silicone oil removal in the second stage. Primary outcome measures were retinal reattachment rate and best-corrected visual acuity.
  
  
  RESULTS
  In all, 37 eyes from 37 patients were included in this study. The mean follow-up duration was 22.9 ± 9.6 months. Retina was reattached in 36 (97.3%) eyes at the last visit. The mean best-corrected visual acuity was 1.76 ± 0.56 logMAR at baseline, which improved to 0.87 ± 0.60 logMAR at the last visit (P < 0.001). Best-corrected visual acuity increased in 31 (83.8%) eyes, remained unchanged in 5 (13.5%) eyes, and decreased in 1 (2.7%) eye at last visit compared with baseline.
  
  
  CONCLUSIONS
  Low-dose (2 mg) triamcinolone acetonide intravitreal injection as an adjunct to vitrectomy and silicone oil tamponade in treating proliferative vitreoretinopathy (grade C or D) appears to be effective and safe.
authors.affiliation: Joint Shantou International Eye Center of the Shantou University & Chinese University of Hong Kong, Shantou, China.
authors.forename: Weiqi
authors.initials: W
authors.lastname: Chen
authors.forename: Haoyu
authors.initials: H
authors.lastname: Chen
authors.forename: Ping
authors.initials: P
authors.lastname: Hou
authors.forename: Andrew
authors.initials: A
authors.lastname: Fok
authors.forename: Yijun
authors.initials: Y
authors.lastname: Hu
authors.forename: Dennis S C
authors.initials: DS
authors.lastname: Lam
mesh_terms: D000328:Adult; D000368:Aged; D004322:Drainage / Q000379:methods; D058450:Endotamponade; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D058449:Intravitreal Injections; D017075:Laser Coagulation; D019654:Lens Implantation, Intraocular; D008297:Male; D008875:Middle Aged; D018918:Phacoemulsification; D012189:Retrospective Studies; D012827:Silicone Oils / Q000008:administration & dosage*; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*; D014792:Visual Acuity / Q000502:physiology; D014821:Vitrectomy; D018630:Vitreoretinopathy, Proliferative / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D014822:Vitreous Body; D055815:Young Adult
chemical_list: D005938:Glucocorticoids; D012827:Silicone Oils; D014222:Triamcinolone Acetonide